In Phase C, individuals will get ABBV-744 and oral navitoclax. In Section D, individuals will obtain ABBV-744 and ruxolitinib. Contributors will acquire treatment right up until disorder progression or maybe the contributors are not able to tolerate the study drugs. Ubiquitin-related proteins that control The soundness of important Tremendous enhancer-mediated https://abbv-744therapeuticpotent35629.anchor-blog.com/12228033/5-easy-facts-about-abbv-744-brd4-inhibitor-mechanism-of-action-described